Highlights

  • CSL (ASX:CSL) has gone shopping outside its own laboratories, agreeing to pay US$355 million upfront to Swiss biotech Alentis Therapeutics for a share of an experimental antibody aimed at rare kidney and liver
  • The Basel-based company was built on research from Professor Thomas Baumert's laboratory at the University of Strasbourg and France's Inserm.
  • An interim look at 26 patients in the Phase 2 RENAL trial showed improved kidney function and lower protein levels in urine at 24 weeks.
  • Kidney drug developer Dimerix said the first patient in its global Phase 3 trial of DMX-200 in FSGS had completed four continuous years of treatment, including two years in the open-label extension.

CSL (ASX:CSL) has gone shopping outside its own laboratories, agreeing to pay US$355 million upfront to Swiss biotech Alentis Therapeutics for a share of an experimental antibody aimed at rare kidney and liver diseases. The upfront cheque alone is worth well over A$500 million, and the total package could climb to about US$1.6 billion once commercial milestones are counted.

Investors took the deal calmly. CSL shares edged higher on Monday, with one market report putting the gain at just under 1 per cent and the stock changing hands around $175, while the S&P/ASX 200 finished only marginally in positive territory after giving up most of its early gains.

A Large External Bet on Lixudebart

The drug at the centre of the agreement is lixudebart, a monoclonal antibody that targets an exposed form of the protein claudin-1. Alentis describes that protein as a key driver of the inflammation and scarring that destroy organ function in fibrotic diseases of the kidney, liver and lung. The Basel-based company was built on research from Professor Thomas Baumert's laboratory at the University of Strasbourg and France's Inserm.

Under the terms announced on Monday, Alentis can earn up to US$1.2 billion in commercial milestone payments on top of the upfront sum. CSL will fund the remaining clinical program, and once the drug reaches market the partners will split profits 55 per cent to CSL and 45 per cent to Alentis. Two related claudin-1 antibody-drug conjugates stay with Alentis and are outside the deal.

Clinical Development Moves Forward

The lead indication is ANCA-associated vasculitis with rapidly progressive glomerulonephritis, an aggressive autoimmune condition that can push patients towards end-stage kidney failure. An interim look at 26 patients in the Phase 2 RENAL trial showed improved kidney function and lower protein levels in urine at 24 weeks. A separate Phase 1b study, FEGATO, enrolled 41 people with advanced liver fibrosis and reported better liver function after six weeks.

CSL will pay to finish RENAL, run a Phase 3 study in the same vasculitis population, and launch Phase 2 trials in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis, a chronic bile duct disease with few treatment options. CSL's research chief Bill Mezzanotte said the drug could become an important new option to help preserve kidney function and stop progression to end-stage disease. The antibody already holds US Orphan Drug status for idiopathic pulmonary fibrosis.

Healthcare Peers Mark Their Own Milestones

The deal matters because it shows CSL leaning into nephrology, a therapy area it already lists alongside plasma products, vaccines and iron deficiency, and because it marks a sizeable external bet at a time when investors have been demanding clearer growth drivers from the biotech heavyweight.

Elsewhere in the healthcare sector, three smaller companies posted milestones of their own. Kidney drug developer Dimerix said the first patient in its global Phase 3 trial of DMX-200 in FSGS had completed four continuous years of treatment, including two years in the open-label extension. It reported that 89 of 96 eligible trial graduates, or 93 per cent, had rolled into that extension study. Dimerix shares were unchanged at 24 cents.

The Next Markers for CSL

New Zealand wound-care group Aroa Biosurgery released randomised trial data showing its Symphony product closed 55 per cent of hard-to-heal diabetic foot ulcers within 12 weeks, compared with 35 per cent for standard care alone. Medical imaging developer Optiscan said it had lodged a US FDA 510(k) submission for InVue, its device that lets surgeons see tissue at cellular resolution during operations.

For CSL, the next markers to watch are the start of the Phase 3 vasculitis study, fuller RENAL data and any guidance on how the upfront payment will be treated in its financial results. For the small caps, an FDA decision on Optiscan's InVue and continued enrolment updates from Dimerix will be the key catalysts.

What Comes After the Lixudebart Bet?

Attention now turns to the next operational, clinical, exploration or regulatory milestones outlined by CSL, with upcoming results and execution set to determine how the current development pathway progresses.